The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Partial tumor irradiation plus pembrolizumab in treating large advanced solid tumor metastases.
 
Mark Charles Korpics
No Relationships to Disclose
 
Benjamin Ernst Onderdonk
No Relationships to Disclose
 
Rebekah E Dadey
No Relationships to Disclose
 
Jared H Hara
No Relationships to Disclose
 
Lilit Karapetyan
No Relationships to Disclose
 
Yuanyuan Zha
No Relationships to Disclose
 
Theodore Karrison
No Relationships to Disclose
 
Adam C. Olson
Consulting or Advisory Role - RenovoRx
Research Funding - Reflexion Medical; Varian Medical Systems
 
Gini F. Fleming
Honoraria - Physicans' Education Resource
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Celldex (Inst); Compugen (Inst); Compugen (Inst); Corcept Therapeutics (Inst); CytomX Therapeutics (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Iovance Biotherapeutics (Inst); K-Group Beta (Inst); Merck (Inst); Molecular Templates (Inst); P{fizer (Inst); Pfizer (Inst); Plexxikon (Inst); Roche (Inst); Sermonix Pharmaceuticals (Inst); Syros Pharmaceuticals (Inst)
Other Relationship - AstraZeneca (Inst); Caris Life Sciences (Inst); DSI (Inst); Eisai (Inst); Merck (Inst)
(OPTIONAL) Uncompensated Relationships - Abbvie
 
Ralph R. Weichselbaum
Stock and Other Ownership Interests - AquaLung Therapeutics; Boost Therapeutics; Coordination Pharmaceuticals; Cyntegron Therapeutics; Immvira; Magi Therapeutics; Oncosenescence; Reflexion Pharmaceuticals
Honoraria - Highlight Therapeutics; Shuttle Pharmaceuticals
Consulting or Advisory Role - Aettis; AquaLung Therapeutics; AstraZeneca; Coordination Pharmaceuticals; Genus Oncology; Highlight Therapeutics; Merck Serono; Nano proteagen; NkGen Biotech; Reflexion Pharmaceuticals; Sanofi; Shuttle Pharmaceuticals
Research Funding - Regeneron; Varian Medical Systems
Patents, Royalties, Other Intellectual Property - Boost Therapeutics; METHODS AND KITS FOR DIAGNOSIS AND TRIAGE OF PATIENTS WITH COLORECTAL LIVER METASTASES Publication number: 20210115519 Abstract: Methods, assays, and compositions for identifying molecular subtypes of metastatic cancer are disclosed. Methods include dete; Oncosenescence; Reflexion Pharmaceuticals; Tvec
 
Riyue Bao
Patents, Royalties, Other Intellectual Property - PCT/US15/612657 (Cancer Immunotherapy); PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof); PCT/US63/055227 (Methods and Compositions for Treating Autoimmune and Allergic Disorders)
 
Steven J. Chmura
Employment - Astellas Pharma (I); Takeda (I)
Honoraria - Reflexion Medical
Consulting or Advisory Role - AstraZeneca; Genentech
Research Funding - AstraZeneca/MedImmune; BMS; Merck
Patents, Royalties, Other Intellectual Property - UptoDate article
 
Jason J. Luke
Stock and Other Ownership Interests - Actym Therapeutics; Alphamab; Arch Oncology; Kanaph Therapeutics; Mavu Pharmaceutical; NeoTX; NeoTX; Onc.AI; Pyxis; STipe Therapeutics; Tempest Therapeutics
Consulting or Advisory Role - 7 Hills Pharma; Abbvie; Alnylam; Alphamab; Bayer; Bright Peak Therapeutics; Bristol-Myers Squibb; Checkmate Pharmaceuticals; Codiak Biosciences; Crown Bioscience; CStone Pharmaceuticals; Day One Therapeutics; EMD Serono; Endeavor BioMedicines; Flame Biosciences; Genentech; Gilead Sciences; Hotspot Therapeutics; Immunocore; Incyte; Inzen Therapeutics; Janssen; Kadmon; KSQ Therapeutics; Merck; Nektar; Novartis; Onc.AI; Partner Therapeutics; Pfizer; Reflexion Medical; Regeneron; Ribon Therapeutics; Rubius Therapeutics; SERVIER; Silicon Therapeutics; STINGthera; STipe Therapeutics; Synlogic; Synthekine; Tempest Therapeutics; Tesaro; TRex Bio; Werewolf Therapeutics; Xencor; Xilio Therapeutics
Research Funding - Abbvie (Inst); Agios (Inst); Array BioPharma (Inst); Astellas Pharma (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); EMD Serono (Inst); Fstar (Inst); Genmab (Inst); Ikena Oncology (Inst); Immatics (Inst); Incyte (Inst); Kadmon (Inst); KAHR Medical (Inst); Macrogenics (Inst); Merck (Inst); Moderna Therapeutics (Inst); Nektar (Inst); NextCure (Inst); Numab (Inst); Replimune (Inst); Rubius Therapeutics (Inst); Scholar Rock (Inst); Spring bank (Inst); Synlogic (Inst); Takeda (Inst); Tizona Therapeutics, Inc. (Inst); Trishula Therapeutics (Inst); Xencor (Inst)
Patents, Royalties, Other Intellectual Property - Serial #15/612,657 (Cancer Immunotherapy),; Serial #PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof)
Travel, Accommodations, Expenses - Array BioPharma; Bristol-Myers Squibb; EMD Serono; Janssen; Merck; Mersana; Novartis; Pyxis; Reflexion Medical; Xilio Therapeutics